Skip to main content

Insulin Resistance

12
Pipeline Programs
25
Companies
19
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
2
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
583%
Peptide
117%
+ 20 programs with unclassified modality

Competitive Landscape

19 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
1
1
NateglinidePhase 4
VildagliptinPhase 3Small Molecule
BVS857Phase 1
Bayer
BayerLEVERKUSEN, Germany
1 program
1
NateglinidePhase 4
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
AvandiaPhase 3
Genfit
GenfitFrance - Loos
1 program
1
GFT505 80mgPhase 21 trial
Active Trials
NCT01271777Completed22Est. Nov 2011
OrsoBio
OrsoBioCA - Palo Alto
1 program
1
TLC-3595 Dose 1Phase 21 trial
Active Trials
NCT05665751Active Not Recruiting76Est. Dec 2024
Innovation Pharmaceuticals
3 programs
1
KetoconazolePhase 1Small Molecule1 trial
Hypertonic SalineN/A1 trial
No applyN/A1 trial
Active Trials
NCT02761434Completed60Est. May 2017
NCT03244449Completed81Est. Dec 2016
NCT02256865Completed40Est. Oct 2023
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
PolyphenolsPhase 11 trial
Oral Glucose Tolerance TestN/A1 trial
Active Trials
NCT04089332Completed23Est. Jul 2022
NCT00668928Completed20Est. Dec 2007
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AtropinePhase 11 trial
Active Trials
NCT00689208Completed12Est. Nov 2008
Incyte
IncyteDE - Wilmington
1 program
1
INCB13739Phase 11 trial
Active Trials
NCT00398619CompletedEst. Mar 2007
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistatPhase 1Small Molecule
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
Growth hormoneN/A1 trial
LiraglutidePHASE_4Peptide1 trial
Active Trials
NCT00568568Completed8Est. Feb 2010
NCT02403284Completed97Est. Nov 2023
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistatPHASE_1Small Molecule1 trial
Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistatPHASE_1Small Molecule
Active Trials
NCT02203461Completed30Est. Oct 2014
Physical Sciences
Physical SciencesMA - Andover
1 program
Circuit trainingN/A1 trial
Active Trials
NCT04528693Completed49Est. Jun 2025
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
EstradiolN/A1 trial
Active Trials
NCT01605071Completed53Est. Jan 2017
Abbott
AbbottABBOTT PARK, IL
1 program
RosiglitazoneN/A1 trial
Active Trials
NCT00186537Completed47Est. Sep 2008
Enterprise Therapeutics
1 program
Water ControlN/A1 trial
Active Trials
NCT03102463Completed6Est. Jun 2017
Genentech
GenentechCA - Oceanside
1 program
BFKB8488APHASE_11 trial
Active Trials
NCT02593331Completed79Est. Mar 2017
GSK
GSKLONDON, United Kingdom
1 program
AvandiaPHASE_31 trial
Active Trials
NCT00197132Completed18Est. Aug 2003
Novartis
NovartisBASEL, Switzerland
1 program
NateglinidePHASE_41 trial
Active Trials
NCT00259168Completed70Est. Mar 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskLiraglutide
NovartisNateglinide
GSKAvandia
OrsoBioTLC-3595 Dose 1
GenfitGFT505 80mg
GenentechBFKB8488A
Innovation PharmaceuticalsKetoconazole
Gilead SciencesTenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
AstraZenecaAtropine
IncyteINCB13739
Human BioSciencesPolyphenols
Physical SciencesCircuit training
Human BioSciencesOral Glucose Tolerance Test
Innovation PharmaceuticalsHypertonic Saline
Enterprise TherapeuticsWater Control

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 791 patients across 19 trials

NCT02403284Novo NordiskLiraglutide

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

Start: Mar 2013Est. completion: Nov 202397 patients
Phase 4Completed
NCT00259168NovartisNateglinide

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

Start: Jun 2003Est. completion: Mar 200670 patients
Phase 4Completed
NCT00197132GSKAvandia

Study In Patients With Insulin Resistance

Start: Oct 2002Est. completion: Aug 200318 patients
Phase 3Completed
NCT05665751OrsoBioTLC-3595 Dose 1

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Start: Mar 2023Est. completion: Dec 202476 patients
Phase 2Active Not Recruiting
NCT01271777GenfitGFT505 80mg

Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

Start: Jan 2011Est. completion: Nov 201122 patients
Phase 2Completed
NCT02593331GenentechBFKB8488A

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

Start: Oct 2015Est. completion: Mar 201779 patients
Phase 1Completed
NCT02256865Innovation PharmaceuticalsKetoconazole

Hormonal Mechanisms of Sleep Restriction

Start: Oct 2014Est. completion: Oct 202340 patients
Phase 1Completed
NCT02203461Gilead SciencesTenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

Start: Jul 2014Est. completion: Oct 201430 patients
Phase 1Completed
NCT00689208AstraZenecaAtropine

Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity

Start: May 2007Est. completion: Nov 200812 patients
Phase 1Completed
NCT00398619IncyteINCB13739

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Start: Nov 2006Est. completion: Mar 2007
Phase 1Completed
NCT00668928Human BioSciencesPolyphenols

Effect of Dietary Polyphenols on Insulin Sensitivity

Start: Jan 2006Est. completion: Dec 200720 patients
Phase 1Completed
NCT04528693Physical SciencesCircuit training

The Effect of 12-week Circuit Training on Insulin Sensitivity and Endothelial Function in Women With Insulin Resistance

Start: Aug 2020Est. completion: Jun 202549 patients
N/ACompleted
NCT04089332Human BioSciencesOral Glucose Tolerance Test

Insulin Resistance in Adolescents

Start: Oct 2019Est. completion: Jul 202223 patients
N/ACompleted
NCT02761434Innovation PharmaceuticalsHypertonic Saline

The Effect of Vasopressin on Glucose Regulation

Start: Apr 2016Est. completion: May 201760 patients
N/ACompleted
NCT03102463Enterprise TherapeuticsWater Control

The Role of Milk Derived Peptides on Glycaemic Control

Start: Oct 2015Est. completion: Jun 20176 patients
N/ACompleted
NCT03244449Innovation PharmaceuticalsNo apply

New IR Biomarkers (Myokines) in Colombian People

Start: Aug 2014Est. completion: Dec 201681 patients
N/ACompleted
NCT01605071Colorado TherapeuticsEstradiol

Timing Estrogen After MenoPaUSe

Start: Sep 2011Est. completion: Jan 201753 patients
N/ACompleted
NCT00568568Novo NordiskGrowth hormone

Metabolic Studies- Interactions Between GH and Insulin in GHDA

Start: Dec 2007Est. completion: Feb 20108 patients
N/ACompleted
NCT00186537AbbottRosiglitazone

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

Start: Sep 2003Est. completion: Sep 200847 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
25 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.